메뉴 건너뛰기




Volumn 2015, Issue , 2015, Pages

Targeted therapies compared to dacarbazine for treatment of brafv600e metastatic melanoma: A cost-effectiveness analysis

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; DABRAFENIB; DACARBAZINE; VEMURAFENIB;

EID: 84952994892     PISSN: 20902905     EISSN: 20902913     Source Type: Journal    
DOI: 10.1155/2015/505302     Document Type: Conference Paper
Times cited : (21)

References (40)
  • 3
    • 74949143594 scopus 로고    scopus 로고
    • Final version of 2009 AJCC melanoma staging and classification
    • C. M. Balch, J. E. Gershenwald, S.-J. Soong et al., "Final version of 2009 AJCC melanoma staging and classification, " Journal of Clinical Oncology, vol. 27, no. 36, pp. 6199-6206, 2009.
    • (2009) Journal of Clinical Oncology , vol.27 , Issue.36 , pp. 6199-6206
    • Balch, C.M.1    Gershenwald, J.E.2    Soong, S.-J.3
  • 4
    • 79959795786 scopus 로고    scopus 로고
    • Improved survival with vemurafenib in melanoma with BRAF V600E mutation
    • P. B. Chapman, A. Hauschild, C. Robert et al., "Improved survival with vemurafenib in melanoma with BRAF V600E mutation, " New England Journal of Medicine, vol. 364, no. 26, pp. 2507-2516, 2011.
    • (2011) New England Journal of Medicine , vol.364 , Issue.26 , pp. 2507-2516
    • Chapman, P.B.1    Hauschild, A.2    Robert, C.3
  • 5
    • 33947101019 scopus 로고    scopus 로고
    • Patterns of somatic mutation in human cancer genomes
    • C. Greenman, P. Stephens, R. Smith et al., "Patterns of somatic mutation in human cancer genomes, " Nature, vol. 446, pp. 153-158, 2007.
    • (2007) Nature , vol.446 , pp. 153-158
    • Greenman, C.1    Stephens, P.2    Smith, R.3
  • 6
    • 84864285704 scopus 로고    scopus 로고
    • Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, openlabel, phase 3 randomised controlled trial
    • A. Hauschild, J.-J. Grob, L. V. Demidov et al., "Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, openlabel, phase 3 randomised controlled trial, " The Lancet, vol. 380, no. 9839, pp. 358-365, 2012.
    • (2012) The Lancet , vol.380 , Issue.9839 , pp. 358-365
    • Hauschild, A.1    Grob, J.-J.2    Demidov, L.V.3
  • 8
    • 67650491811 scopus 로고    scopus 로고
    • Treatment of metastatic melanoma: An overview
    • S. Bhatia, S. S. Tykodi, and J. A. Thompson, "Treatment of metastatic melanoma: an overview, " Oncology, vol. 23, no. 6, pp. 488-496, 2009.
    • (2009) Oncology , vol.23 , Issue.6 , pp. 488-496
    • Bhatia, S.1    Tykodi, S.S.2    Thompson, J.A.3
  • 9
    • 84873819555 scopus 로고    scopus 로고
    • Which drug, and when, for patients with BRAF-mutant melanoma?
    • S. Jang and M. B. Atkins, "Which drug, and when, for patients with BRAF-mutant melanoma?" The Lancet Oncology, vol. 14, no. 2, pp. e60-e69, 2013.
    • (2013) The Lancet Oncology , vol.14 , Issue.2 , pp. e60-e69
    • Jang, S.1    Atkins, M.B.2
  • 11
    • 84879467934 scopus 로고    scopus 로고
    • Ipilimumab, vemurafenib, dabrafenib, and trametinib: Synergistic competitors in the clinical management of BRAF mutant malignantmelanoma
    • J. J. Luke and F. S. Hodia, "Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignantmelanoma, " The Oncologist, vol. 18, no. 6, pp. 717-725, 2013.
    • (2013) The Oncologist , vol.18 , Issue.6 , pp. 717-725
    • Luke, J.J.1    Hodia, F.S.2
  • 12
    • 84925662170 scopus 로고    scopus 로고
    • National Comprehensive Cancer Network (NCCN) , National Comprehensive Cancer Network (NCCN), Philadelphia, Pa, USA
    • National Comprehensive Cancer Network (NCCN), National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Antiemesis (Version 2.2014), National Comprehensive Cancer Network (NCCN), Philadelphia, Pa, USA, 2014, http://www.nccn.org/professionals/physician gls/pdf/ antiemesis.pdf.
    • (2014) National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Antiemesis (Version 2 2014)
  • 17
    • 84859443897 scopus 로고    scopus 로고
    • Fee comparisons of treatments for nonmelanoma skin cancer in a private practice academic setting
    • L. S. Wilson, M. Pregenzer, R. Basu et al., "Fee comparisons of treatments for nonmelanoma skin cancer in a private practice academic setting, " Dermatologic Surgery, vol. 38, no. 4, pp. 570-584, 2012.
    • (2012) Dermatologic Surgery , vol.38 , Issue.4 , pp. 570-584
    • Wilson, L.S.1    Pregenzer, M.2    Basu, R.3
  • 18
    • 0030708771 scopus 로고    scopus 로고
    • Guidelines on acute infectious diarrhea in adults. The Practice Parameters Committee of the American College of Gastroenterology
    • H. L. DuPont, "Guidelines on acute infectious diarrhea in adults. The Practice Parameters Committee of the American College of Gastroenterology, " The American Journal of Gastroenterology, vol. 92, no. 11, pp. 1962-1975, 1997.
    • (1997) The American Journal of Gastroenterology , vol.92 , Issue.11 , pp. 1962-1975
    • Dupont, H.L.1
  • 19
    • 82355163146 scopus 로고    scopus 로고
    • Clinical presentation andmanagement of hand-foot skin reaction associated with sorafenib in combinationwith cytotoxic chemotherapy: Experience in breast cancer
    • P. Gomez and M. E. Lacouture, "Clinical presentation andmanagement of hand-foot skin reaction associated with sorafenib in combinationwith cytotoxic chemotherapy: experience in breast cancer, " The Oncologist, vol. 16, no. 11, pp. 1508-1519, 2011.
    • (2011) The Oncologist , vol.16 , Issue.11 , pp. 1508-1519
    • Gomez, P.1    Lacouture, M.E.2
  • 20
    • 34447095906 scopus 로고    scopus 로고
    • Palmar-plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centre
    • J. D. Webster-Gandy, C. How, and K. Harrold, "Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre, " European Journal of Oncology Nursing, vol. 11, no. 3, pp. 238-246, 2007.
    • (2007) European Journal of Oncology Nursing , vol.11 , Issue.3 , pp. 238-246
    • Webster-Gandy, J.D.1    How, C.2    Harrold, K.3
  • 21
    • 84896714827 scopus 로고    scopus 로고
    • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): Extended follow-up of a phase 3, randomised, open-label study
    • G. A. McArthur, P. B. Chapman, C. Robert et al., "Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study, " The Lancet Oncology, vol. 15, no. 3, pp. 323-332, 2014.
    • (2014) The Lancet Oncology , vol.15 , Issue.3 , pp. 323-332
    • McArthur, G.A.1    Chapman, P.B.2    Robert, C.3
  • 23
    • 0020445539 scopus 로고
    • Aconvenient approximation of life expectancy (the 'DEALE'). I. Validation of the method
    • J.R. Beck, J. P. Kassirer, and S. G. Pauker, "Aconvenient approximation of life expectancy (the 'DEALE'). I. validation of the method, " The American Journal of Medicine, vol. 73, no. 6, pp. 883-888, 1982.
    • (1982) The American Journal of Medicine , vol.73 , Issue.6 , pp. 883-888
    • Beck, J.R.1    Kassirer, J.P.2    Pauker, S.G.3
  • 24
    • 0026937441 scopus 로고
    • New DEALEs: Other approximations of life expectancy
    • E. Keeler and R. Bell, "New DEALEs: other approximations of life expectancy, " MedicalDecisionMaking, vol. 12, no. 4, pp. 307-311, 1992.
    • (1992) MedicalDecisionMaking , vol.12 , Issue.4 , pp. 307-311
    • Keeler, E.1    Bell, R.2
  • 25
    • 68149158282 scopus 로고    scopus 로고
    • Societal preference values for advanced melanoma health states in the United Kingdom and Australia
    • K. M. Beusterien, S. M. Szabo, S. Kotapati et al., "Societal preference values for advanced melanoma health states in the United Kingdom and Australia, " British Journal of Cancer, vol. 101, no. 3, pp. 387-389, 2009.
    • (2009) British Journal of Cancer , vol.101 , Issue.3 , pp. 387-389
    • Beusterien, K.M.1    Szabo, S.M.2    Kotapati, S.3
  • 28
    • 84903741191 scopus 로고    scopus 로고
    • Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: Quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine
    • J. J. Grob, M. M. Amonkar, S. Martin-Algarra et al., "Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine, " Annals of Oncology, vol. 25, no. 7, pp. 1428-1436, 2014.
    • (2014) Annals of Oncology , vol.25 , Issue.7 , pp. 1428-1436
    • Grob, J.J.1    Amonkar, M.M.2    Martin-Algarra, S.3
  • 30
    • 0037443674 scopus 로고    scopus 로고
    • Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors
    • L. S. Elting, S. B. Cantor, C. G. Martin et al., "Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors, " Cancer, vol. 97, no. 6, pp. 1541-1550, 2003.
    • (2003) Cancer , vol.97 , Issue.6 , pp. 1541-1550
    • Elting, L.S.1    Cantor, S.B.2    Martin, C.G.3
  • 31
    • 52649097540 scopus 로고    scopus 로고
    • Optimal cost-effectiveness decisions: The role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI)
    • G. R. Barton, A. H. Briggs, and E. A. L. Fenwick, "Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI), " Value in Health, vol. 11, no. 5, pp. 886-897, 2008.
    • (2008) Value in Health , vol.11 , Issue.5 , pp. 886-897
    • Barton, G.R.1    Briggs, A.H.2    Fenwick, E.A.L.3
  • 32
    • 84910598214 scopus 로고    scopus 로고
    • Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma
    • P. Curl, I. Vujic, L. J. van 't Veer, S. Ortiz-Urda, J. G. Kahn, and A. T. Slominski, "Cost-effectiveness of treatment strategies for BRAF-mutated metastatic melanoma, " PLoS ONE, vol. 9, no. 9, 2014.
    • (2014) PLoS ONE , vol.9 , Issue.9
    • Curl, P.1    Vujic, I.2    Van Veer, L.J.3    Ortiz-Urda, S.4    Kahn, J.G.5    Slominski, A.T.6
  • 33
    • 1542634778 scopus 로고    scopus 로고
    • Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: A critical appraisal
    • C. Evans, M. Tavakoli, and B. Crawford, "Use of quality adjusted life years and life years gained as benchmarks in economic evaluations: a critical appraisal, " Health Care Management Science, vol. 7, no. 1, pp. 43-49, 2004.
    • (2004) Health Care Management Science , vol.7 , Issue.1 , pp. 43-49
    • Evans, C.1    Tavakoli, M.2    Crawford, B.3
  • 34
    • 84907360483 scopus 로고    scopus 로고
    • Updating cost-effectiveness-The curious resilience of the 50, 000-per-QALY threshold
    • P. J. Neumann, J. T. Cohen, and M. C. Weinstein, "Updating cost-effectiveness-the curious resilience of the 50, 000-per-QALY threshold, "TheNewEngland Journal ofMedicine, vol. 371, no. 9, pp. 796-797, 2014.
    • (2014) The New England Journal OfMedicine , vol.371 , Issue.9 , pp. 796-797
    • Neumann, P.J.1    Cohen, J.T.2    Weinstein, M.C.3
  • 35
    • 84879021680 scopus 로고    scopus 로고
    • Ipilimumab in 2nd line treatment of patients with advanced melanoma: A cost-effectiveness analysis
    • V. Barzey, M. B. Atkins, L. P. Garrison, Y. Asukai, S. Kotapati, and J. R. Penrod, "Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis, " Journal of Medical Economics, vol. 16, no. 2, pp. 202-212, 2013.
    • (2013) Journal of Medical Economics , vol.16 , Issue.2 , pp. 202-212
    • Barzey, V.1    Atkins, M.B.2    Garrison, L.P.3    Asukai, Y.4    Kotapati, S.5    Penrod, J.R.6
  • 36
    • 84877327961 scopus 로고    scopus 로고
    • NICE's end of life decision making scheme: Impact on population health
    • Article ID f1363
    • M. Collins and N. Latimer, "NICE's end of life decision making scheme: impact on population health, " British Medical Journal, vol. 346, no. 7905, Article ID f1363, 2013.
    • (2013) British Medical Journal , vol.346 , Issue.7905
    • Collins, M.1    Latimer, N.2
  • 37
    • 85020643915 scopus 로고    scopus 로고
    • American Cancer Society
    • American Cancer Society, Cancer Drug Coverage in Health InsuranceMarketplace Plans, 2014, http://www.acscan.org/content/ wp-content/uploads/2014/03/Marketplace formularies whitepaper.pdf.
    • (2014) Cancer Drug Coverage in Health InsuranceMarketplace Plans
  • 39
    • 0031017851 scopus 로고    scopus 로고
    • Patient preferences for oral versus intravenous palliative chemotherapy
    • G. Liu, E. Franssen, M. I. Fitch, and E. Warner, "Patient preferences for oral versus intravenous palliative chemotherapy, " Journal of Clinical Oncology, vol. 15, no. 1, pp. 110-115, 1997.
    • (1997) Journal of Clinical Oncology , vol.15 , Issue.1 , pp. 110-115
    • Liu, G.1    Franssen, E.2    Fitch, M.I.3    Warner, E.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.